Chronic Allograft Dysfunction

Clinics in Chest Medicine

Volumn 32, Issue 2, 2011, Pages 311-326

  Knoop, Christiane ^a   Estenne, Marc ^a  

^a ERASME HOSPITAL   (Belgium)

Author keywords

Bronchiolitis obliterans; Bronchiolitis obliterans syndrome; Chronic lung allograft dysfunction; Lung transplantation; Macrolides; Neutrophilic reversible allograft airways dysfunction

Indexed keywords

AZITHROMYCIN; BIOLOGICAL MARKER; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

AIRWAY OBSTRUCTION; ALLOIMMUNITY; AUTOIMMUNITY; BRONCHIOLITIS OBLITERANS; CELL FUNCTION; CHRONIC GRAFT REJECTION; CLINICAL FEATURE; GASTROESOPHAGEAL REFLUX; HUMAN; HYPERCHOLESTEROLEMIA; INFECTION RISK; LEUKOCYTE ACTIVATION; LUNG FIBROSIS; LUNG FUNCTION TEST; LUNG GRAFT REJECTION; LUNG TRANSPLANTATION; LUNG VENTILATION; LYMPH NODE IRRADIATION; PATHOGENESIS; PATHOPHYSIOLOGY; PLEURISY; PRIORITY JOURNAL; PUVA; RETRANSPLANTATION; REVIEW; RISK FACTOR; THORAX RADIOGRAPHY;

ANTI-BACTERIAL AGENTS; BRONCHIOLITIS OBLITERANS; CHRONIC DISEASE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG DISEASES; LUNG TRANSPLANTATION; LYMPHATIC IRRADIATION; MACROLIDES; NEUTROPHILS; PHOTOPHERESIS; POSTOPERATIVE COMPLICATIONS; REOPERATION; RESPIRATORY FUNCTION TESTS;

EID: 79954589557     PISSN: 02725231     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccm.2011.02.009     Document Type: Review

References (109)

1. Burke C.M., Theodore J., Dawkins K.D., et al. Post-transplant obliterative bronchiolitis and other late lung sequelae in human heart-lung transplantation. Chest 1984, 86:824-829.
2. Christie J.D., Edwards L.B., Kucheryavaya A.Y., et al. The Registry of the International Society for Heart and Lung Transplantation: twenty-seventh official adult lung and heart-lung transplant report-2010. J Heart Lung Transplant 2010, 29:1004-1018.
3. Glanville A.R. Bronchoscopic monitoring after lung transplantation. Semin Respir Crit Care Med 2010, 31:208-221.
4. Estenne M., Maurer J.R., Boehler A., et al. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J Heart Lung Transplant 2002, 21:297-310.
5. Jackson C.H., Sharples L.D., McNeil K., et al. Acute and chronic onset of bronchiolitis obliterans syndrome (BOS): are they different entities?. J Heart Lung Transplant 2002, 21:658-666.
6. Finlen Copeland C.A., Snyder L.D., Zaas D.W., et al. Survival after bronchiolitis obliterans syndrome among bilateral lung transplant recipients. Am J Respir Crit Care Med 2010, 182:784-789.
7. Bankier A.A., Muylem A.V., Knoop C., et al. BOS in heart-lung transplant recipients: diagnosis with expiratory CT. Radiology 2001, 218:533-539.
8. de Jong P.A., Dodd J.D., Coxson H.O., et al. Bronchiolitis obliterans following lung transplantation: early detection using computed tomographic scanning. Thorax 2006, 61:799-804.
9. Heng D., Sharples L.D., McNeil K., et al. Bronchiolitis obliterans syndrome: incidence, natural history, prognosis, and risk factors. J Heart Lung Transplant 1998, 17:1255-1263.
10. Bando K., Paradis I.L., Similo S., et al. Obliterative bronchiolitis after lung and heart-lung transplantation. An analysis of risk factors and management. J Thorac Cardiovasc Surg 1995, 110:4-13.
11. Valentine V.G., Robbins R.C., Berry G.J., et al. Actuarial survival of heart-lung and bilateral sequential lung transplant recipients with obliterative bronchiolitis. J Heart Lung Transplant 1996, 15:371-383.
12. van den Berg J.W., Geertsma A., van de Bij W., et al. Bronchiolitis obliterans syndrome after lung transplantation and health-related quality of life. Am J Respir Crit Care Med 2000, 161:1937-1941.
13. Martinu T., Howell D.N., Davis R.D., et al. Pathologic correlates of bronchiolitis obliterans syndrome in pulmonary retransplant recipients. Chest 2006, 129:1016-1023.
14. Gerhardt S.G., McDyer J.F., Girgis R.E., et al. Maintenance azithromycin therapy for bronchiolitis obliterans syndrome: results of a pilot study. Am J Respir Crit Care Med 2003, 168:121-125.
15. Verleden G.M., Dupont L.J. Azithromycin therapy for patients with bronchiolitis obliterans syndrome after lung transplantation. Transplantation 2004, 77:1465-1467.
16. Yates B., Murphy D.M., Forrest I.A., et al. Azithromycin reverses airflow obstruction in established bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 2005, 172:772-775.
17. Shitrit D., Bendayan D., Gidon S., et al. Long-term azithromycin use for treatment of bronchiolitis obliterans syndrome in lung transplant recipients. J Heart Lung Transplant 2005, 24:1440-1443.
18. Verleden G.M., Vanaudenaerde B.M., Dupont L.J., et al. Azithromycin reduces airway neutrophilia and IL-8 in patients with bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 2006, 174:566-570.
19. Porhownik N.R., Batobara W., Kepron W., et al. Effect of maintenance azithromycin on established bronchiolitis obliterans syndrome in lung transplnat patients. Can Respir J 2008, 15:199-202.
20. Gottlieb J., Szangolies J., Koehnlein T., et al. Long-term azithromycin for bronchiolitis obliterans syndrome after lung transplantation. Transplantation 2008, 85:36-41.
21. Benden C., Boehler A. Long-term clarithromycin therapy in the management of lung transplant recipients. Transplantation 2009, 87:1538-1540.
22. Verleden G.M., Vos R., De Vleeschauwer S.I., et al. Obliterative bronchiolitis following lung transplantation: from old to new concepts?. Transpl Int 2009, 22:771-779.
23. Pakhale S.S., Hadjiliadis D., Howell D.N., et al. Upper lobe fibrosis: a novel manifestation of chronic allograft dysfunction in lung transplantation. J Heart Lung Transplant 2005, 24:1260-1268.
24. Woodrow J.P., Shlobin O.A., Barnett S.D., et al. Comparison of bronchiolitis obliterans syndrome to other forms of chronic lung allograft dysfunction after lung transplantation. J Heart Lung Transplant 2010, 29:1159-1164.
25. Ferrer J., Roldan J., Roman A., et al. Acute and chronic pleural complications in lung transplantation. J Heart Lung Transplant 2003, 22:1217-1225.
26. McManus T.E., Milne D.G., Whyte K.F., et al. Exudative bronchiolitis after lung transplantation. J Heart Lung Transplant 2008, 27:276-281.
27. Vos R., Vanaudenaerde B.M., De Vleeschauwer S.I., et al. Follicular bronchiolitis: a rare cause of bronchiolitis obliterans syndrome after lung transplantation: a case report. Am J Transplant 2009, 9:644-650.
28. Akindipe O., Fernandez-Bussy S., Jantz M., et al. Obliterative bronchiolitis in lung allografts removed at retransplant for intractable airway problems. Respirology 2009, 14:601-605.
29. Halloran P.F., Homik J., Goes N., et al. The " injury response": a concept linking nonspecific injury, acute rejection, and long-term transplant outcomes. Transplant Proc 1997, 29:79-81.
30. Egan J.J. Obliterative bronchiolitis after lung transplantation: a repetitive multiple injury airway disease. Am J Respir Crit Care Med 2004, 170:931-932.
31. Opelz G., Süsal C., Ruhenstroth A., et al. Impact of HLA compatibility on lung transplant survival and evidence for an HLA restriction phenomenon: a collaborative transplant study report. Transplantation 2010, 90:912-917.
32. Keogh A., Kaan A., Doran T., et al. HLA mismatching and outcome in heart, heart-lung and single lung transplantation. J Heart Lung Transplant 1995, 14:444-451.
33. Schulman L.L., Weinberg A.D., McGregor C., et al. Mismatches at the HLA-DR and HLA-B loci are risk factors for acute rejection after lung transplantation. Am J Respir Crit Care Med 1998, 157:1833-1837.
34. Quantz M.A., Bennett L.E., Meyer D.M., et al. Does human leukocyte antigen matching influence the outcome of lung transplantation? An analysis of 3,549 lung transplantations. J Heart Lung Transplant 2000, 19:473-479.
35. Girnita A.L., McCurry K.R., Iacono A.T., et al. HLA-specific antibodies are associated with high-grade and persistent-recurrent lung allograft acute rejection. J Heart Lung Transplant 2004, 23:1135-1141.
36. Girnita A.L., Duquesnoy R., Yousem S.A., et al. HLA-specific antibodies are risk factors for lymphocytic bronchiolitis and chronic lung allograft dysfunction. Am J Transplant 2005, 5:131-138.
37. Jaramillo A., Smith M.A., Phelan D., et al. Development of ELISA-detected anti-HLA antibodies precedes the development of bronchiolitis obliterans syndrome and correlates with progressive decline in pulmonary function after lung transplantation. Transplantation 1999, 67:1155-1156.
38. Palmer S.M., Davis R.D., Hadjiliadis D., et al. Development of an antibody specific to major histocompatibility antigens detectable by flow cytometry after lung transplant is associated with bronchiolitis obliterans syndrome. Transplantation 2002, 74:799-804.
39. Girnita A.L., McCurry K.R., Zeevi A. Increased lung allograft failure in patients with HLA-specific antibody. Clin Transpl 2007, 231-239.
40. Jaramillo A., Smith C.R., Maruyama T., et al. Anti-HLA class I antibody binding to airway epithelial cells induces production of fibrogenic growth factors and apoptotic cell death: a possible mechanism for bronchiolitis obliterans syndrome. Hum Immunol 2003, 64:521-529.
41. Yousem S.A. Significance of clinically silent untreated mild acute cellular rejection in lung allograft recipients. Hum Pathol 1996, 27:269-273.
42. Knoop C., Estenne M. Acute and chronic rejection after lung transplantation. Semin Respir Crit Care Med 2006, 27:521-533.
43. Hopkins P.M., Aboyoun C.L., Chhajed P.N., et al. Association of minimal rejection in lung transplant recipients with obliterative bronchiolitis. Am J Respir Crit Care Med 2004, 170:1022-1026.
44. Khalifah A.P., Hachem R.R., Chakinala M.M., et al. Minimal acute rejection after lung transplantation: a risk for bronchiolitis obliterans syndrome. Am J Transplant 2005, 5:2022-2030.
45. Hachem R.R., Khalifah A.P., Chakinala M.M., et al. The significance of a single episode of minimal acute rejection after lung transplantation. Transplantation 2005, 80:1406-1413.
46. Ross D.J., Marchevsky A., Kramer M., et al. Refractoriness of airflow obstruction associated with isolated lymphocytic bronchiolitis/bronchitis in pulmonary allografts. J Heart Lung Transplant 1997, 16:832-838.
47. Husain A.N., Siddiqui M.T., Holmes E.W., et al. Analysis of risk factors for the development of bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 1999, 159:829-833.
48. Glanville A.R., Aboyoun C.L., Havryk A., et al. Severity of lymphocytic bronchiolitis predicts long-term outcome after lung transplantation. Am J Respir Crit Care Med 2008, 177:1033-1040.
49. Burton C.M., Iversen M., Scheike T., et al. Is lymphocytic bronchiolitis a marker of acute rejection? An analysis of 2,697 transbronchial biopsies after lung transplantation. J Heart Lung Transplant 2008, 27:1128-1134.
50. Glanville A.R. Antibody-mediated rejection in lung transplantation: myth or reality?. J Heart Lung Transplant 2010, 29:395-400.
51. Morrell M.R., Patterson G.A., Trulock E.P., et al. Acute antibody-mediated rejection after lung transplantation. J Heart Lung Transplant 2009, 28:96-100.
52. Magro C.M., Abbas A.E., Seilstad K., et al. C3d and the septal microvasculature as a predictor of chronic lung allograft dysfunction. Hum Immunol 2006, 67:274-283.
53. Burlingham W.J., Love R.B., Jankowska-Gan E., et al. IL-17-dependent cellular immunity to collagen type V predisposes to obliterative bronchiolitis in human lung transplants. J Clin Invest 2007, 117:3498-3506.
54. Goers T.A., Ramachandran S., Aloush A., et al. De novo production of K-alpha1 tubulin-specific antibodies: role in chronic lung allograft rejection. Hum Immunol 2008, 180:4487-4494.
55. Tiriveedhi V., Angaswamy N., Weber J., et al. Lipid raft facilitated ligation of K-alpha1-tubulin by specific antibodies on epithelial cells: role in pathogenesis of chronic rejection following human lung transplantation. Biochem Biophys Res Commun 2010, 399:251-255.
56. Nath D.S., Basha H.I., Mohanakumar T. Antihuman leukocyte antigen antibody-induced autoimmunity: role in chronic rejection. Curr Opin Organ Transplant 2010, 15:16-20.
57. Shilling R.A., Wilkes D.S. Immunobiology of chronic lung allograft dysfunction: new insights from the bench and beyond. Am J Transplant 2009, 9:1714-1718.
58. Kastelijn E.A., van Moorsel C.H., Rijkers G.T., et al. Polymorphisms in innate immunity genes associated with development of bronchiolitis obliterans after lung transplantation. J Heart Lung Transplant 2010, 29:665-671.
59. Botha P., Archer L., Anderson R.L., et al. Pseudomonas aeruginosa colonization of the allograft after lung transplantation and the risk of bronchiolitis obliterans syndrome. Transplantation 2008, 85:771-774.
60. Weigt S.S., Elashoff R.M., Huang C., et al. Aspergillus colonization of the lung allograft is a risk factor for bronchiolitis obliterans syndrome. Am J Transplant 2009, 9:1903-1911.
61. Valentine V.G., Gupta M.R., Walker J.E., et al. Effect of etiology and timing of respiratory tract infections on development of bronchiolitis obliterans syndrome. J Heart Lung Transplant 2009, 28:163-169.
62. Kumar D., Husain S., Chen M.H., et al. A prospective molecular surveillance study evaluating the clinical impact of community-acquired respiratory viruses in lung transplant recipients. Transplantation 2010, 89:1028-1033.
63. Gottlieb J., Schulz T.F., Welte T., et al. Community-acquired respiratory viral infections in lung transplant recipients: a single season cohort study. Transplantation 2009, 87:1530-1537.
64. Glanville A.R., Gencay M., Tamm M., et al. Chlamydia pneumoniae infection after lung transplantation. J Heart Lung Transplant 2005, 24:131-136.
65. Kotsimbos T.C., Snell G.I., Levvey B., et al. Chlamydia pneumoniae serology in donors and recipients and the risk of bronchiolitis obliterans syndrome after lung transplantation. Transplantation 2005, 79:269-275.
66. Neurohr C., Huppmann P., Leuchte H., et al. Human herpesvirus 6 in bronchalveolar lavage fluid after lung transplantation: a risk factor for bronchiolitis obliterans syndrome?. Am J Transplant 2005, 5:2982-2991.
67. Valentine V.G., Weill D., Gupta M.R., et al. Ganciclovir for cytomegalovirus: a call for indefinite prophylaxis in lung transplantation. J Heart Lung Transplant 2008, 27:875-881.
68. Tamm M., Aboyoun C.L., Chhajed P.N., et al. Treated cytomegalovirus pneumonia is not associated with bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 2004, 170:1120-1123.
69. Davis C.S., Shankaran V., Kovacs E.J., et al. Gastroesophageal reflux disease after lung transplantation: pathophysiology and implications for treatment. Surgery 2010, 148:737-744.
70. Blondeau K., Mertens V., Vanaudenaerde B.A., et al. Gastro-oesophageal reflux and gastric aspiration in lung transplant patients with or without chronic rejection. Eur Respir J 2008, 31:707-713.
71. D'Ovidio F., Mura M., Tsang M., et al. Bile acid aspiration and the development of bronchiolitis obliterans after lung transplantation. J Thorac Cardiovasc Surg 2005, 129:1144-1152.
72. Cantu E., Appel J.Z., Hartwig M.G., et al. Early fundoplication prevents chronic allograft dysfunction in patients with gastroesophageal reflux disease. Ann Thorac Surg 2004, 78:1142-1151.
73. Davis R.D., Lau C.L., Eubanks S., et al. Improved lung allograft function after fundoplication in patients with gastroesophageal reflux disease undergoing lung transplantation. J Thorac Cardiovasc Surg 2003, 125:533-542.
74. Robertson A.G., Ward C., Pearson J.P., et al. Lung transplantation, gastroesophageal reflux, and fundoplication. Ann Thorac Surg 2010, 89:653-660.
75. Snell G.I., Westall G.P. The contribution of airway ischemia and vascular remodelling to the pathophysiology of bronchiolitis obliterans syndrome and chronic lung allograft dysfunction. Curr Opin Organ Transplant 2010, 15:558-562.
76. Daud S.A., Yusen R.D., Meyers B.F., et al. Impact of immediate primary lung allograft dysfunction on bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 2007, 175:507-513.
77. Belperio J.A., Keane M.P., Burdik M.D., et al. Role of CXCR2/CXCR2 ligands in vascular remodelling during bronchiolitis obliterans syndrome. J Clin Invest 2005, 115:1150-1162.
78. Douglas I.S., Nicolls M.R. Chemokine-mediated angiogenesis: an essential link in the evolution of airway fibrosis?. J Clin Invest 2005, 115:1133-1136.
79. Dhillon G.S., Zamora M.R., Roos J.E., et al. Lung transplant airway hypoxia: a diathesis to fibrosis?. Am J Respir Crit Care Med 2010, 182:230-236.
80. Hachem R.R., Chakinala M.M., Yusen R.D., et al. The predictive value of bronchiolitis obliterans syndrome stage 0-p. Am J Respir Crit Care Med 2004, 169:468-472.
81. Lama I.N., Murray S., Mumford J.A., et al. Prognostic value of bronchiolitis obliterans syndrome stage 0-p in single-lung transplant recipients. Am J Respir Crit Care Med 2005, 172:379-383.
82. Estenne M., Van Muylem A., Knoop C., et al. Detection of obliterative bronchiolitis by indexes of ventilation distribution. Am J Respir Crit Care Med 2000, 162:1047-1051.
83. Reynaud-Gaubert M., Thomas P., Badier M., et al. Early detection of airway involvement in obliterative bronchiolitis after lung transplantation. Functional and bronchoalveolar lavage cell findings. Am J Respir Crit Care Med 2000, 161:1924-1929.
84. Van Muylem A., Knoop C., Estenne M. Early detection of chronic pulmonary allograft dysfunction by exhaled biomarkers. Am J Respir Crit Care Med 2007, 175:731-736.
85. Van Muylem A., Scillia P., Knoop C., et al. Single-breath test in lateral decubitus reflects function of single lungs grafted for emphysema. J Appl Physiol 2006, 100:834-838.
86. Van Muylem A., Gevenois P.A., Kallinger E., et al. Single-breath test in lateral decubitus reflects function of single lungs grafted for interstitial lung disease. J Appl Physiol 2008, 104:224-229.
87. Gabbay E., Haydn Walters E., Orsida B., et al. In stable lung transplant recipients, exhaled nitric oxide levels positively correlate with airway neutrophilia and bronchial epithelial iNOS. Am J Respir Crit Care Med 1999, 160:2093-2099.
88. Gabbay E., Walters E.H., Orsida B., et al. Post-lung transplant bronchiolitis obliterans syndrome (BOS) is characterized by increased exhaled nitric oxide levels and epithelial inducible nitric oxide synthase. Am J Respir Crit Care Med 2000, 162:2182-2187.
89. Zheng L., Whitford H.M., Orsida B., et al. The dynamics and associations of airway neutrophilia post lung transplantation. Am J Transplant 2006, 6:599-608.
90. Vos R., Cordemans C., Vanaudenaerde B.M., et al. Exhaled carbon monoxide as a noninvasive marker of airway neutrophilia after lung transplantation. Transplantation 2009, 87:1579-1583.
91. Fisher A.J., Gabbay E., Small T., et al. Cross sectional study of exhaled nitric oxide levels following lung transplantation. Thorax 1998, 53:454-458.
92. Verleden G.M., Dupont L.J., Van Raemdonck D.E., et al. Accuracy of exhaled nitric oxide measurements for the diagnosis of bronchiolitis obliterans syndrome after lung transplantation. Transplantation 2004, 78:730-733.
93. Brugiere O., Thabut G., Mal H., et al. Exhaled NO may predict the decline in lung function in bronchiolitis obliterans syndrome. Eur Respir J 2005, 25:813-819.
94. Dupont L.J., Dewandeleer Y., Vanaudenaerde B.M., et al. The pH of exhaled breath condensate of patients with allograft rejection after lung transplantation. Am J Transplant 2006, 6:1486-1492.
95. Allen D.J., Fildes J.E., Yonan N., et al. Changes in induced sputum in the presence of bronchiolitis obliterans syndrome and correlation with spirometry in single and bilateral lung transplant recipients. J Heart Lung Transplant 2005, 24:88-91.
96. Bankier A.A., Van Muylem A., Scillia P., et al. Air trapping in heart-lung transplant recipients: variability of anatomic distribution and extent at sequential expiratory thin-section CT. Radiology 2003, 229:737-742.
97. Gast K.K., Zaporozhan J., Ley S., et al. (3)He-MRI in follow-up of lung transplant recipients. Eur Radiol 2004, 14:78-85.
98. Vos R., Vanaudenaerde B.M., Ottevaere A., et al. Long-term azithromycin therapy for bronchiolitis obliterans syndrome: divide and conquer?. J Heart Lung transplant 2010, 29:1358-1368.
99. Jain R., Hachem R.R., Morrell M.R., et al. Azithromycin is associated with increased survival in lung transplant recipients with bronchiolitis obliterans syndrome. J Heart Lung Transplant 2010, 29:531-537.
100. Vos R., Vanaudenaerde B.M., Verleden S.E., et al. A randomized placebo-controlled trial of azithromycin to prevent bronchiolitis obliterans syndrome after lung transplantation. Eur Respir J 2011, 37:164-172.
101. Johnson B.A., Iacono A.T., Zeevi A., et al. Statin use is associated with improved function and survival of lung allografts. Am J Respir Crit Care Med 2003, 167:1271-1278.
102. Murphy D.M., Forrest I.A., Corris P.A., et al. Simvastatin attenuates release of neutrophilic and remodeling factors from primary bronchial epithelial cells derived from stable lung transplant recipients. Am J Physiol Lung Cell Mol Physiol 2008, 294:L592-L599.
103. Fisher A.J., Rutherford R.M., Bozzino J., et al. The safety and efficacy of total lymphoid irradiation in progressive bronchiolitis obliterans syndrome after lung transplantation. Am J Transplant 2005, 5:537-543.
104. Benden C., Speich R., Wanger C., et al. Extracorporeal photopheresis after lung transplantation: a 10-year single-center experience. Transplantation 2008, 86:1625-1627.
105. Morrell M.R., Despotis G.J., Lublin D.M., et al. The efficacy of photopheresis for bronchiolitis obliterans syndrome after lung transplantation. J Heart Lung Transplant 2010, 29:424-431.
106. Novick R.J., Stitt L.W., Al-Kattan K., et al. Pulmonary retransplantation: predictors of graft function and survival in 230 patients. Pulmonary Retransplant Registry. Ann Thorac Surg 1998, 65:227-234.
107. Brugière O., Thabut G., Castier Y., et al. Lung retransplantation for bronchiolitis obliterans syndrome: long-term follow-up in a series of 15 recipients. Chest 2003, 123:1832-1837.
108. Strueber M., Fischer S., Gottlieb J., et al. Long-term outcome after pulmonary retransplantation. J Thorac Cardiovasc Surg 2006, 132:407-412.
109. Müller C., Görler H., Ballmann M., et al. Pulmonary retransplantation in paediatric patients: a justified therapeutic option? A single-centre experience. Eur J Cardiothorac Surg 2011, 39:201-205.